Barbara Denecke
Medizinische Onkologie und Hämatologie · Dept. I
Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer
Schuler A, Omlin A, Husarik D, Denecke B, Rothermundt C. Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer. Annals of Clinical Case Reports 2021
Dec 13, 2021Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer
Dec 13, 2021Annals of Clinical Case Reports 2021
Schuler Alexandra, Omlin Aurelius, Husarik Daniela B., Denecke Barbara, Rothermundt Christian
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H, Weisel K. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 2011; 91:729-735.
Dec 15, 2011Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Dec 15, 2011Ann Hematol 2011; 91:729-735
Heyne Nils, Denecke Barbara, Guthoff Martina, Oehrlein Katharina, Kanz Lothar, Häring Hans-Ulrich, Weisel Katja
Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever?
Denecke B, Bigalke B, Haap M, Overkamp D, Lehnert H, Haas C. Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever?. Mayo Clin Proc 2010; 85:1016-20.
Nov 1, 2010Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever?
Nov 1, 2010Mayo Clin Proc 2010; 85:1016-20
Denecke Barbara, Bigalke Boris, Haap Michael, Overkamp Dietrich, Lehnert Hendrik, Haas Christian S
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
Horger M, Pereira P, Claussen C, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol 2008; 81:386-96.
May 1, 2008Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
May 1, 2008Br J Radiol 2008; 81:386-96
Horger Marius, Pereira Philippe, Claussen Claus Detlef, Kanz Lothar, Vonthein Reinhard, Denecke Barbara, Driessen Christoph
The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.
Apr 15, 2007The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Apr 15, 2007Cancer 2007; 109:1617-26
Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller M, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2002; 101:259-64.
Jun 28, 2002Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Jun 28, 2002Blood 2002; 101:259-64
Burchert Andreas, Wölfl Stefan, Schmidt Manuel, Brendel Cornelia, Denecke Barbara, Cai Dali, Odyvanova Larissa, Lahaye Tanja, Müller Martin, Berg Thomas, Gschaidmeier Harald, Wittig Burghardt, Hehlmann Rüdiger, Hochhaus Andreas, Neubauer Andreas